157 related articles for article (PubMed ID: 25180623)
1. Managed care implications in managing rheumatoid arthritis.
Owens GM
Am J Manag Care; 2014 May; 20(7 Suppl):S145-52. PubMed ID: 25180623
[TBL] [Abstract][Full Text] [Related]
2. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.
Ollendorf DA; Peterson AN; Doyle J; Huse DM
Am J Manag Care; 2002 May; 8(7 Suppl):S203-13. PubMed ID: 12022236
[TBL] [Abstract][Full Text] [Related]
3. The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis.
Symmons D; Tricker K; Roberts C; Davies L; Dawes P; Scott DL
Health Technol Assess; 2005 Sep; 9(34):iii-iv, ix-x, 1-78. PubMed ID: 16153351
[TBL] [Abstract][Full Text] [Related]
4. A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings.
Lubeck DP
Pharmacoeconomics; 2001; 19(8):811-8. PubMed ID: 11596833
[TBL] [Abstract][Full Text] [Related]
5. Core management principles in rheumatoid arthritis to help guide managed care professionals.
Agarwal SK
J Manag Care Pharm; 2011; 17(9 Suppl B):S03-8. PubMed ID: 22073933
[TBL] [Abstract][Full Text] [Related]
6. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs.
Lanes SF; Lanza LL; Radensky PW; Yood RA; Meenan RF; Walker AM; Dreyer NA
Arthritis Rheum; 1997 Aug; 40(8):1475-81. PubMed ID: 9259428
[TBL] [Abstract][Full Text] [Related]
7. Implications for managed care and specialty pharmacy in rheumatoid arthritis.
Cardarelli WJ
Am J Manag Care; 2012 Dec; 18(13 Suppl):S315-24. PubMed ID: 23327519
[TBL] [Abstract][Full Text] [Related]
8. Incorporating the treat-to-target concept in rheumatoid arthritis.
Ruderman EM; Nola KM; Ferrell S; Sapir T; Cameron DR
J Manag Care Pharm; 2012; 18(9):1-18. PubMed ID: 23206239
[TBL] [Abstract][Full Text] [Related]
9. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
[TBL] [Abstract][Full Text] [Related]
10. Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.
Hewlett S; Almeida C; Ambler N; Blair PS; Choy E; Dures E; Hammond A; Hollingworth W; Kadir B; Kirwan J; Plummer Z; Rooke C; Thorn J; Turner N; Pollock J
Health Technol Assess; 2019 Oct; 23(57):1-130. PubMed ID: 31601357
[TBL] [Abstract][Full Text] [Related]
11. Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients.
Mennini FS; Marcellusi A; Gitto L; Iannone F
Clin Drug Investig; 2017 Apr; 37(4):375-386. PubMed ID: 28074337
[TBL] [Abstract][Full Text] [Related]
12. Economic and quality-of-life impact of rheumatoid arthritis.
Doyle JJ
Manag Care; 2001 Jul; 10(7 Suppl):15-8. PubMed ID: 11729429
[TBL] [Abstract][Full Text] [Related]
13. Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis.
Her M; Kavanaugh A
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S107-11. PubMed ID: 23078839
[TBL] [Abstract][Full Text] [Related]
14. Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.
Heather EM; Payne K; Harrison M; Symmons DP
Pharmacoeconomics; 2014 Feb; 32(2):109-34. PubMed ID: 24338344
[TBL] [Abstract][Full Text] [Related]
15. Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey.
Hamuryudan V; Direskeneli H; Ertenli I; Inanc M; Karaaslan Y; Oksel F; Ozbek S; Pay S; Terzioglu E; Balkan Tezer D; Hacibedel B; Akkoc N
Clin Exp Rheumatol; 2016; 34(6):1033-1037. PubMed ID: 27749224
[TBL] [Abstract][Full Text] [Related]
16. Disease course and healthcare costs of a cohort of rheumatoid arthritis patients from Turkey.
Ayan G; Esatoglu SN; Hatemi G; Hamuryudan V
Rheumatol Int; 2020 Jul; 40(7):1037-1044. PubMed ID: 32253500
[TBL] [Abstract][Full Text] [Related]
17. [A multicenter cross-sectional study on the health related quality of life of patients with rheumatoid arthritis using a revised Japanese version of the arthritis impact measurement scales version 2 (AIMS 2), focusing on the medical care costs and their associative factors].
Hashimoto A; Sato H; Nishibayahi Y; Shiino Y; Kutsuna T; Ishihara Y; Hoshi K; Fujimori J; Tsuboi S; Kondo H; Akizuki M; Moroi Y; Yoshida S
Ryumachi; 2002 Feb; 42(1):23-39. PubMed ID: 11925904
[TBL] [Abstract][Full Text] [Related]
18. Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission.
Barnabe C; Thanh NX; Ohinmaa A; Homik J; Barr SG; Martin L; Maksymowych WP
Ann Rheum Dis; 2013 Oct; 72(10):1664-8. PubMed ID: 23117244
[TBL] [Abstract][Full Text] [Related]
19. Coverage inequalities of new therapies for rheumatoid arthritis in a managed care setting.
Gallup E
Manag Care Interface; 2001 Jul; 14(7):52-4, 57-8, 69. PubMed ID: 11481817
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era.
Hsieh PH; Wu O; Geue C; McIntosh E; McInnes IB; Siebert S
Ann Rheum Dis; 2020 Jun; 79(6):771-777. PubMed ID: 32245893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
